Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$130.0B
2,043M shares
52-week range
$42.52 – $68.64
83% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
P/S (TTM)
2.7
EV / FCF (TTM)
14.5
Bristol Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
www.bms.comNo one on the platform currently holds BMY.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 977,051 | $59.3M |
| Bridgewater Associatesas of 2026-03-31 | 241,689 | $14.7M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-02 | $0.6300 | 2026-08-03 |
| 2026-04-02 | $0.6300 | 2026-05-01 |
| 2026-01-02 | $0.6300 | 2026-02-02 |
| 2025-10-03 | $0.6200 | 2025-11-03 |
| 2025-07-03 | $0.6200 | 2025-08-01 |
| 2025-04-04 | $0.6200 | 2025-05-01 |
| 2025-01-03 | $0.6200 | 2025-02-03 |
| 2024-10-04 | $0.6000 | 2024-11-01 |
| 2024-07-05 | $0.6000 | 2024-08-01 |
| 2024-04-04 | $0.6000 | 2024-05-01 |
No one on the platform has traded BMY yet.
| 2024-01-04 | $0.6000 | 2024-02-01 |
| 2023-10-05 | $0.5700 | 2023-11-01 |
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 18.7% | — | — | — | ||
| Rev. Growth % | -0.2% | 2.5% | ||||
| Profit Margin % | 14.6% | 8.5% | 8.4% | |||
| Free Cash Flow Margin % | 26.7% | 28.5% | 25.9% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is -5.9% on the P/E track.
At today's price, your expected annual return is -1.7% on the P/E track.
At today's price, your expected annual return is +1.7% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $49.6B | +3.3% | $6.93 | $6.35–$7.22 | 9.3× | 16 |
| 2027 | $48.1B | -3.0% | $6.55 | $5.94–$7.45 | 9.8× | 16 |
| 2028 | $41.9B | -12.8% | $5.63 | $4.47–$6.54 | 11.4× | 8 |
| 2029 | $38.0B | -9.5% | $5.08 | $4.80–$5.28 | 12.6× | 5 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-30 | $1.60 | $2.04 | +27.5% |
| 2026-04-30 | $1.42 | $1.58 | +11.3% |
| 2026-02-05 | $1.23 | $1.26 | +2.4% |
| 2025-10-30 | $1.52 | $1.63 | +7.2% |
| 2025-07-31 | $1.09 | $1.46 | +33.9% |
| 2025-04-24 | $1.49 | $1.80 | +20.8% |
| 2025-02-06 | $1.47 | $1.67 | +13.6% |
| 2024-10-31 | $1.49 |
| $1.80 |
| +20.8% |
| $100.3B |
| — |
| HCAHCA Healthcare, Inc. | $425.49 | -0.34% | $92.1B | — |
| MCKMcKesson Corporation | $910.95 | +3.34% | $106.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Stifel y'day reiterated $CTNM Buy-$28 and said -- CTNM announced today that PIPE-307/JNJ-5120/, their selective M1R antagonist, failed its ph2 study in MDD. $JNJ $BMY AGMB PLRX VCRE Here's what Stifel went on to say in its note: https://x.com/Quantumup1/status/2099820032914026501?s=20
View on StockTwits ↗
$SLS This current short rigged $2.3B Market cap isn't even Close to What Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. reddit.com/r/sellasLifescience $ABBV and $BMY who own Aza VEN know It ain't BAT Causing the Miraculous Survival.
View on StockTwits ↗
$SLS just a quick reminder: Michael Frascello of $JNJ has been studying GPS/REGAL for 1.5 years called it a “game changer” in AML. Katherine Bach Kalin on the board of SLS was part of $BMY huge 74b purchase of $CELG and purchase a huge amount of shares 9 months ago. Michael Anglestein of AstraZenica also stated GPS was a game changer for AML patients. Not one of the board have sold a single share either, I’m down; but not out!
View on StockTwits ↗$SLS $ABBV $BMY BAT for the SLS Control arm Failed 3 Aml remission maintenance trials. what do you think that means? Viale-M Failed in First Remission Viale-T Failed in post Transplant Maintenance Viale C and Verona - Failed
View on StockTwits ↗$SLS $ABBV $BMY Viale-M, T and C Failed
View on StockTwits ↗$SLS The $ABBV $BMY People Know its GPs. This current short rigged $2.3B Market cap isn't even Close to What is Gps is worth the moment the Imminent Phase 3 Results are Announced. $MRNA added $40B in a day for a Reason $RVMD added Nearly $30B the day its P3 results were announced. https://www.reddit.com/r/sellasLifescience/comments/1weo6k2/comment/p9fbhtj/?screen_view_count=1
View on StockTwits ↗$SLS at 60 events the IDMC UNBLINDED ACTUAL PHASE 3 MOS and IMMUNE RESPONSE DATA! Unblinded Actual Median Overall Survival and Immune Response data from the ongoing P3. $ABBV $BMY Own BAT - they all Know Gps is doing what its done in all 7 prior trials, including 2 Phase 2’s for AML REMISSION MAINTENANCE. and Yes BAT Failed 3 large P3’s and 2 for AML MAINTENANCE - Viale-M - Viale-T FAILED.
View on StockTwits ↗
$COYA $XBI $BMY Remember this previous post. Sticking to my 🔫 Things can change in a split second.
View on StockTwits ↗
$SLS A lot of you are VERY confused today. We've had drops before, but why is this one different? Why does this feel like doom? Simple: Reality Before yesterday, many have felt it. Many of you started to believe it. Many of you started to venture into the "could it be" territory. And then it hit. Perfect storm. Market up, $SLS tanking. - CEO self-imposed Quiet Period feels like cowardness and hiding - Models that so many relied on are now showing a coin toss - Reality that the run up was tied to tutes capitalizing on a dead ticker - Reality that Shorts remain strong and appear in more control - Reality that the hype was from 10 ad hoc patients of an AML study - Reality that the CEO has been suspect since jump street -Reality that competitors $MRK and $BMY collaborated with $SLS and walked before the collab was complete - Reality $SLS's team history is one of legal and regulatory concerns - Reality that all the BS you thought Bears shared now makes complete sense. $XBI
View on StockTwits ↗
$BMY Bristol Myers Squibb on clear support here around $63. HSBC price target raised from $60 to $65 ⬆️
View on StockTwits ↗
$CELG (now $BMY ) investors — there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/celgene-investor-settlement
View on StockTwits ↗Cantor reiterated an Overweight rating on $CYTK after its fireside chat w/ mgmt. $EWTX $BMY TECX TENC AZN NVO BAYRY Here's what Cantor said in its note to investors: https://x.com/Quantumup1/status/2098376353619870023?s=20
View on StockTwits ↗
@Haginger $KYTX the $NVS / $BMY headlines didn’t help but if you listen to the Wells Fargo conference call on the Quartr app they explain the differences in their approach that likely lead to those unfortunate incidents for the other companies. They were very clear about the safety profile of their product so if anything this should become a tailwind as they work towards approval.
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.